ArticleeLife2025
Bacteriophage infection drives loss of β-lactam resistance in methicillin-resistant
Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Bacteriophage Challenge Drives Genomic and Proteomic Remodeling and Alters Antibiotic Resistance in a Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Phage Intolerance Impacts Antibiotic Susceptibility and Virulence in Staphylococcus aureus.Current microbiology · 2026Article
- Lethal permeabilization of host bacteria to small-molecule compounds during phage penetration.Nature communications · 2026Article
- Prophages in Skin Pathogens: From Virulence to Therapy.Pathogens (Basel, Switzerland) · 2026Review
- In vitro concentration-dependent inhibition of early biofilm formation by Staphylococcus aureus isolated from dairy cattle using a bacteriophage cocktail.BMC veterinary research · 2026Article
- [Antibiotics and phages: effects of combined therapy on susceptibility and resistance of bacterial pathogens].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026Review
- Immuno-phage synergy driven by fitness costs: turning bacterial phage resistance into therapeutic gain through evolutionary traps.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Bacteriophage (phage) therapy is a promising means to combat drug-resistant bacterial pathogens. Infection by phage can select for mutations in bacterial populations that confer resistance against phage infection. However, resistance against phage can yield evolutionary trade-offs of biomedical relevance. Here, we report the discovery that infection by certain staphylococcal phages sensitizes different strains of methicillin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.